- Home
- Campus
- Exploring the ´tides: Medical Miracle for Obesity?
L&H - Exploring the ´tides: Medical Miracle for Obesity?
Exploring the ´tides: Medical Miracle for Obesity?
Image
Objectives
Drugs developed for the treatment of diabetes such as semaglutide (marketed as Ozempic or Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro or Zepbound) are being used to decrease the weight of obesity risks:
- Who are the best candidates for this application?
- What are the risks and side effects?
- What might the impact to the industry be?
Content
The World Obesity Federation estimates 38% of the global population older than five years is classified as overweight or obese. That figure might balloon to as much as 51% by 2035. A serious medical problem itself, obesity is also associated with cardiovascular diseases, hypertension, hepatic steatosis, sleep apnea syndrome, metabolic abnormalities like type 2 diabetes and dyslipidemia, musculoskeletal disorders, and even cancer. Being obese or overweight can also significantly impact a person’s psychosocial health. Drugs initially targeting Type 2 diabetes have been found to be promising weight-loss treatment alternatives.
Participants' Profile
This webinar is suitable for all levels of life insurance professionals, including underwriting, claims, and product development. Attendees may earn one ALU continuing education credit.
Image
Sessions
This virtual event was held on September 25. Replays are available at the links below.
Speaker
Image
Richard Braun, MD (Chief Medical Director, SCOR US L&H)
Already have an account?
Login and Enroll